0
Upcoming Allied Market Research
2023
Vitiligo Drugs Market

Vitiligo Drugs Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Report Code: A10445
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Vitiligo Drugs Market

Request Now !

Vitiligo is a hypopigmentation skin disorder characterized by the white patches on the skin that causes the loss of skin color due to low concentration of melanin in the skin cells. It affects the skin on all parts of the body, hair and inside of the mouth. Vitiligo is not life threatening disorder, however it is found in the people with dark skin and it affected people may feel stressful and have issues about their appearance. The common symptoms of vitiligo include the whitening of the skin and development of white patches on the skin anywhere on the body. Vitiligo disorder found in the age of 40. The exact cause of vitiligo is not known. The researcher found that it is an autoimmune disorder, in which the person’s own immune system falsely acts against the skin cells which produces melanin. Treatment for vitiligo can restore the color to the affected spot on the skin. However, it cannot completely prevent skin discoloration. “Vitiligo Society” in Europe providing the funds for research projects with developing effective and safe treatments for patients and establishing the real causes of vitiligo as well. 

Vitiligo-Drugs

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

 As the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the “World Health Organization” announcing it a public health emergency. The global impacts of the COVID-19 pandemic are already starting to be felt, and will significantly affect the vitiligo drugs market in 2020. COVID-19 can affect the global economy in three main ways by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America market contributes for the largest market share for Vitiligo Treatment and dominate overall market. This attributed to the factors including, increasing incidence of skin disorder such as vitiligo, increasing adoption rate of phototherapy treatment and rising investment in healthcare facilities.  However, Europe is considered as the second large market share for vitiligo treatment due to the presence of major market player, rising investment in research and development activities with the undergoing severe clinical trial. Whereas,  Asia Pacific is anticipated to expand the vitiligo drug market due to the rising government funding, growing adoption rate of new technology and drug and increasing medical tourism in countries. 

In 2019, “American Skin Association” (ASA) declared funding for 18 new grants for skin cancer and disease research. The ASA and its affiliates invested over US$ 50 million for the treatment of melanoma, psoriasis, and vitiligo. “American Academy of Dermatology” reported that in 2017, around150,000 patient were treated for vitiligo during 2013 in the U.S. and also announced that Vitiligo is listed among 24 skin diseases. “National Center for Biotechnology Information” (NCBI), in 2017, approximately 0.5-1% of the global population was diagnosed with vitiligo and 8.8% of India’s population was diagnosed with vitiligo.

The factors such as increasing incidence of vitiligo disorder, changing lifestyle, rising awareness among the individuals, availability of appropriate treatment, Government undertaken initiatives to develop novel treatments for vitiligo, increasing development of new novel therapy and drug discovery, increasing clinical trial studies for launching new drug. Rising demand for the vitiligo treatment, increasing R&D activities are drive the growth of vitiligo drug market. However, the factors which restrain the growth of vitiligo treatment market such as high cost of treatment and stringent regulation for the drug development. The major opportunities available for vitiligo drug market includes, increasing investment in R&D for developing new drug, rising launch of new product therapy, increasing awareness among the individuals and presence of favorable government policies. 

New Product launch to flourish the market:

Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. At present, there is no cure for vitiligo however, some drugs help restore the skin tone. Topical corticosteroids are prescribed as first-line treatment for vitiligo and inflammatory disease and It help in regain skin color. Other drug product such as tacrolimus or pimecrolimus, are used in the treatment of individuals who experience comparatively small areas of depigmentation

In 2017, “Aclaris Therapeutics, Inc.” has introduce “Confluence Life Sciences, Inc.”, a company focused on development of kinase inhibitors for the treatment of autoimmune disorders such as alopecia areata, vitiligo, and atopic dermatitis.

In 218, “Aclaris Therapeutics, Inc.”, has launched “ATI 502” is a topically administered inhibitor of janus kinase (JAK), that is being developed for the treatment of alopecia areata, atopic dermatitis, androgenetic alopecia, and vitiligo.

In 2019, "Dr Reddy's Laboratories” has launched “Melgain lotion”, a patented drug approved for treatment of vitiligo. It is effectively used in combination with other treatment methods for best results. It lightens the skin by increasing the elimination of melanin from skin cells.

In 2018, “STRATA Skin Sciences”, has launched “XTRAC S3 308nm Laser”. This is used for the treatment of skin disorders such as psoriasis and vitiligo. The XTRAC laser utilizes therapeutic UVB light for the treatment of affected skin areas without damaging surrounding healthy skin.

Key benefits of the report:

  • This study presents the analytical depiction of the global vitiligo drugs market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global vitiligo drugs market share.
  • The current market is quantitatively analyzed to highlight the global vitiligo drugs market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global vitiligo drugs market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the Vitiligo Drugs Market research report:

  • Who are the leading market player’s active in vitiligo drugs market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the vitiligo drugs market?
  • What are the projections for the future that will help in taking further strategic steps?

Vitiligo Drugs Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Treatment
  • Drug Class
  • Therapy
  • Surgery
By Type
  • Segmental
  • Non Segmental
By Route of Administration
  • Oral Route
  • Topical Route
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Bristol - Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals Ltd., Applied Biology, Inc., F. Hoffmann-La Roche AG, Dr. Reddy’s Laboratories Ltd., Boston Pharmaceuticals, Dermavant Sciences, Inc., Aclaris Therapeutics, Inc., GlaxoSmithKline plc, Pfizer, Inc.
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: VITILIGO DRUGS MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Drug Class

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Surgery

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: VITILIGO DRUGS MARKET, BY TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Type

    • 5.2. Segmental

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Non Segmental

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: VITILIGO DRUGS MARKET, BY ROUTE OF ADMINISTRATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Route Of Administration

    • 6.2. Oral Route

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Topical Route

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: VITILIGO DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospital Pharmacies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacies

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Online Pharmacies

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: VITILIGO DRUGS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Treatment

      • 8.2.3. Market Size and Forecast, By Type

      • 8.2.4. Market Size and Forecast, By Route Of Administration

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Vitiligo Drugs Market

        • 8.2.7.1. Market Size and Forecast, By Treatment
        • 8.2.7.2. Market Size and Forecast, By Type
        • 8.2.7.3. Market Size and Forecast, By Route Of Administration
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel
      • 8.2.8. Canada Vitiligo Drugs Market

        • 8.2.8.1. Market Size and Forecast, By Treatment
        • 8.2.8.2. Market Size and Forecast, By Type
        • 8.2.8.3. Market Size and Forecast, By Route Of Administration
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel
      • 8.2.9. Mexico Vitiligo Drugs Market

        • 8.2.9.1. Market Size and Forecast, By Treatment
        • 8.2.9.2. Market Size and Forecast, By Type
        • 8.2.9.3. Market Size and Forecast, By Route Of Administration
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Treatment

      • 8.3.3. Market Size and Forecast, By Type

      • 8.3.4. Market Size and Forecast, By Route Of Administration

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Vitiligo Drugs Market

        • 8.3.7.1. Market Size and Forecast, By Treatment
        • 8.3.7.2. Market Size and Forecast, By Type
        • 8.3.7.3. Market Size and Forecast, By Route Of Administration
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel
      • 8.3.8. Germany Vitiligo Drugs Market

        • 8.3.8.1. Market Size and Forecast, By Treatment
        • 8.3.8.2. Market Size and Forecast, By Type
        • 8.3.8.3. Market Size and Forecast, By Route Of Administration
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel
      • 8.3.9. Italy Vitiligo Drugs Market

        • 8.3.9.1. Market Size and Forecast, By Treatment
        • 8.3.9.2. Market Size and Forecast, By Type
        • 8.3.9.3. Market Size and Forecast, By Route Of Administration
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel
      • 8.3.10. Spain Vitiligo Drugs Market

        • 8.3.10.1. Market Size and Forecast, By Treatment
        • 8.3.10.2. Market Size and Forecast, By Type
        • 8.3.10.3. Market Size and Forecast, By Route Of Administration
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel
      • 8.3.11. UK Vitiligo Drugs Market

        • 8.3.11.1. Market Size and Forecast, By Treatment
        • 8.3.11.2. Market Size and Forecast, By Type
        • 8.3.11.3. Market Size and Forecast, By Route Of Administration
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel
      • 8.3.12. Russia Vitiligo Drugs Market

        • 8.3.12.1. Market Size and Forecast, By Treatment
        • 8.3.12.2. Market Size and Forecast, By Type
        • 8.3.12.3. Market Size and Forecast, By Route Of Administration
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel
      • 8.3.13. Rest Of Europe Vitiligo Drugs Market

        • 8.3.13.1. Market Size and Forecast, By Treatment
        • 8.3.13.2. Market Size and Forecast, By Type
        • 8.3.13.3. Market Size and Forecast, By Route Of Administration
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Treatment

      • 8.4.3. Market Size and Forecast, By Type

      • 8.4.4. Market Size and Forecast, By Route Of Administration

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Vitiligo Drugs Market

        • 8.4.7.1. Market Size and Forecast, By Treatment
        • 8.4.7.2. Market Size and Forecast, By Type
        • 8.4.7.3. Market Size and Forecast, By Route Of Administration
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel
      • 8.4.8. Japan Vitiligo Drugs Market

        • 8.4.8.1. Market Size and Forecast, By Treatment
        • 8.4.8.2. Market Size and Forecast, By Type
        • 8.4.8.3. Market Size and Forecast, By Route Of Administration
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel
      • 8.4.9. India Vitiligo Drugs Market

        • 8.4.9.1. Market Size and Forecast, By Treatment
        • 8.4.9.2. Market Size and Forecast, By Type
        • 8.4.9.3. Market Size and Forecast, By Route Of Administration
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel
      • 8.4.10. South Korea Vitiligo Drugs Market

        • 8.4.10.1. Market Size and Forecast, By Treatment
        • 8.4.10.2. Market Size and Forecast, By Type
        • 8.4.10.3. Market Size and Forecast, By Route Of Administration
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel
      • 8.4.11. Australia Vitiligo Drugs Market

        • 8.4.11.1. Market Size and Forecast, By Treatment
        • 8.4.11.2. Market Size and Forecast, By Type
        • 8.4.11.3. Market Size and Forecast, By Route Of Administration
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel
      • 8.4.12. Thailand Vitiligo Drugs Market

        • 8.4.12.1. Market Size and Forecast, By Treatment
        • 8.4.12.2. Market Size and Forecast, By Type
        • 8.4.12.3. Market Size and Forecast, By Route Of Administration
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel
      • 8.4.13. Malaysia Vitiligo Drugs Market

        • 8.4.13.1. Market Size and Forecast, By Treatment
        • 8.4.13.2. Market Size and Forecast, By Type
        • 8.4.13.3. Market Size and Forecast, By Route Of Administration
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel
      • 8.4.14. Indonesia Vitiligo Drugs Market

        • 8.4.14.1. Market Size and Forecast, By Treatment
        • 8.4.14.2. Market Size and Forecast, By Type
        • 8.4.14.3. Market Size and Forecast, By Route Of Administration
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel
      • 8.4.15. Rest of Asia Pacific Vitiligo Drugs Market

        • 8.4.15.1. Market Size and Forecast, By Treatment
        • 8.4.15.2. Market Size and Forecast, By Type
        • 8.4.15.3. Market Size and Forecast, By Route Of Administration
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Treatment

      • 8.5.3. Market Size and Forecast, By Type

      • 8.5.4. Market Size and Forecast, By Route Of Administration

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Vitiligo Drugs Market

        • 8.5.7.1. Market Size and Forecast, By Treatment
        • 8.5.7.2. Market Size and Forecast, By Type
        • 8.5.7.3. Market Size and Forecast, By Route Of Administration
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel
      • 8.5.8. South Africa Vitiligo Drugs Market

        • 8.5.8.1. Market Size and Forecast, By Treatment
        • 8.5.8.2. Market Size and Forecast, By Type
        • 8.5.8.3. Market Size and Forecast, By Route Of Administration
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel
      • 8.5.9. Saudi Arabia Vitiligo Drugs Market

        • 8.5.9.1. Market Size and Forecast, By Treatment
        • 8.5.9.2. Market Size and Forecast, By Type
        • 8.5.9.3. Market Size and Forecast, By Route Of Administration
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel
      • 8.5.10. UAE Vitiligo Drugs Market

        • 8.5.10.1. Market Size and Forecast, By Treatment
        • 8.5.10.2. Market Size and Forecast, By Type
        • 8.5.10.3. Market Size and Forecast, By Route Of Administration
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel
      • 8.5.11. Argentina Vitiligo Drugs Market

        • 8.5.11.1. Market Size and Forecast, By Treatment
        • 8.5.11.2. Market Size and Forecast, By Type
        • 8.5.11.3. Market Size and Forecast, By Route Of Administration
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel
      • 8.5.12. Rest of LAMEA Vitiligo Drugs Market

        • 8.5.12.1. Market Size and Forecast, By Treatment
        • 8.5.12.2. Market Size and Forecast, By Type
        • 8.5.12.3. Market Size and Forecast, By Route Of Administration
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Dermavant Sciences, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Incyte Corporation

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Aclaris Therapeutics, Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Dr. Reddy’s Laboratories Ltd.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. GlaxoSmithKline Plc

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Bristol - Myers Squibb

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Pfizer, Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Clinuvel Pharmaceuticals Ltd.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Applied Biology, Inc.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Boston Pharmaceuticals

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. F. Hoffmann-La Roche AG

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VITILIGO DRUGS MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL VITILIGO DRUGS MARKET FOR DRUG CLASS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL VITILIGO DRUGS MARKET FOR THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL VITILIGO DRUGS MARKET FOR SURGERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL VITILIGO DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL VITILIGO DRUGS MARKET FOR SEGMENTAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL VITILIGO DRUGS MARKET FOR NON SEGMENTAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL VITILIGO DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL VITILIGO DRUGS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL VITILIGO DRUGS MARKET FOR TOPICAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL VITILIGO DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL VITILIGO DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL VITILIGO DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL VITILIGO DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL VITILIGO DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA VITILIGO DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. U.S. VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 22. U.S. VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. U.S. VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 26. CANADA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. CANADA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE VITILIGO DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. ITALY VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. ITALY VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. ITALY VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. ITALY VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. UK VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 55. UK VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. UK VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 57. UK VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC VITILIGO DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. CHINA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. CHINA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. CHINA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 74. CHINA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 80. INDIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. INDIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. AUSTRALIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. THAILAND VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. MALAYSIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. INDONESIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. REST OF ASIA PACIFIC VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. LAMEA VITILIGO DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. BRAZIL VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. SOUTH AFRICA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 120. SAUDI ARABIA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 124. UAE VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 125. UAE VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 126. UAE VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 127. UAE VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 128. ARGENTINA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 132. REST OF LAMEA VITILIGO DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA VITILIGO DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA VITILIGO DRUGS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA VITILIGO DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 136. DERMAVANT SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 137. DERMAVANT SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 138. DERMAVANT SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 139. DERMAVANT SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 140. DERMAVANT SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. INCYTE CORPORATION: KEY EXECUTIVES
  • TABLE 142. INCYTE CORPORATION: COMPANY SNAPSHOT
  • TABLE 143. INCYTE CORPORATION: OPERATING SEGMENTS
  • TABLE 144. INCYTE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 145. INCYTE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. ACLARIS THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 147. ACLARIS THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 148. ACLARIS THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 149. ACLARIS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 150. ACLARIS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 152. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 153. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 154. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 155. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 157. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 158. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 159. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 160. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. BRISTOL - MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 162. BRISTOL - MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 163. BRISTOL - MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 164. BRISTOL - MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 165. BRISTOL - MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 167. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 168. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 169. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 170. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. CLINUVEL PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 172. CLINUVEL PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 173. CLINUVEL PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 174. CLINUVEL PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 175. CLINUVEL PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. APPLIED BIOLOGY, INC.: KEY EXECUTIVES
  • TABLE 177. APPLIED BIOLOGY, INC.: COMPANY SNAPSHOT
  • TABLE 178. APPLIED BIOLOGY, INC.: OPERATING SEGMENTS
  • TABLE 179. APPLIED BIOLOGY, INC.: PRODUCT PORTFOLIO
  • TABLE 180. APPLIED BIOLOGY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. BOSTON PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 182. BOSTON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 183. BOSTON PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 184. BOSTON PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 185. BOSTON PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 186. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 187. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 188. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 189. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 190. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL VITILIGO DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL VITILIGO DRUGS MARKET
  • FIGURE 3. SEGMENTATION VITILIGO DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN VITILIGO DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVITILIGO DRUGS MARKET
  • FIGURE 11. VITILIGO DRUGS MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. VITILIGO DRUGS MARKET FOR DRUG CLASS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. VITILIGO DRUGS MARKET FOR THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. VITILIGO DRUGS MARKET FOR SURGERY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. VITILIGO DRUGS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 16. VITILIGO DRUGS MARKET FOR SEGMENTAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. VITILIGO DRUGS MARKET FOR NON SEGMENTAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. VITILIGO DRUGS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 19. VITILIGO DRUGS MARKET FOR ORAL ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. VITILIGO DRUGS MARKET FOR TOPICAL ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. VITILIGO DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 22. VITILIGO DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. VITILIGO DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. VITILIGO DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: VITILIGO DRUGS MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. DERMAVANT SCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. DERMAVANT SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. DERMAVANT SCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. INCYTE CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. INCYTE CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. INCYTE CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ACLARIS THERAPEUTICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ACLARIS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ACLARIS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. BRISTOL - MYERS SQUIBB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. BRISTOL - MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. BRISTOL - MYERS SQUIBB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. CLINUVEL PHARMACEUTICALS LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. CLINUVEL PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. CLINUVEL PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. APPLIED BIOLOGY, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. APPLIED BIOLOGY, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. APPLIED BIOLOGY, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. BOSTON PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. BOSTON PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. BOSTON PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. F. HOFFMANN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Vitiligo Drugs Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers